On November 9, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, reported that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual meeting of the Society for Neuro-Oncology (SNO), which will be held from 17-20 November in Tampa, FL (Press release, Kazia Therapeutics, NOV 9, 2022, View Source [SID1234623596]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will build on key findings previously presented at the ASCO (Free ASCO Whitepaper) and ESMO (Free ESMO Whitepaper) annual meetings earlier in the year.

In addition, Professor Matt Dun from the Hunter Medical Research Institute at the University of Newcastle, Australia, will present the latest data from his ongoing research with paxalisib in diffuse midline gliomas, an aggressive form of childhood brain cancer.